Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab PK in Renal Impairment
NCT02275156Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2014
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evolocumab in hyperlipidemia and mixed dyslipidemia, sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration at 57 days and Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration at 57 days. Started Aug 2014; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT02275156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275156.